 Lymphocytes, Tumor-Infiltrating
"Lymphocytes, Tumor-Infiltrating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
| Descriptor ID |
D016246
|
| MeSH Number(s) |
A11.118.637.555.567.650 A15.145.229.637.555.567.650 A15.382.490.555.567.650
|
| Concept/Terms |
Lymphocytes, Tumor-Infiltrating- Lymphocytes, Tumor-Infiltrating
- Lymphocytes, Tumor Infiltrating
- Tumor-Infiltrating Lymphocytes
- Lymphocyte, Tumor-Infiltrating
- Tumor Infiltrating Lymphocytes
- Tumor-Infiltrating Lymphocyte
Tumor-Derived Activated Cells- Tumor-Derived Activated Cells
- Activated Cell, Tumor-Derived
- Activated Cells, Tumor-Derived
- Tumor Derived Activated Cells
- Tumor-Derived Activated Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphocytes, Tumor-Infiltrating".
Below are MeSH descriptors whose meaning is more specific than "Lymphocytes, Tumor-Infiltrating".
This graph shows the total number of publications written about "Lymphocytes, Tumor-Infiltrating" by people in this website by year, and whether "Lymphocytes, Tumor-Infiltrating" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 2 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 0 | 3 | 3 | | 2013 | 3 | 1 | 4 | | 2014 | 4 | 4 | 8 | | 2015 | 5 | 2 | 7 | | 2016 | 9 | 6 | 15 | | 2017 | 5 | 4 | 9 | | 2018 | 9 | 4 | 13 | | 2019 | 7 | 9 | 16 | | 2020 | 5 | 6 | 11 | | 2021 | 5 | 11 | 16 | | 2022 | 2 | 8 | 10 | | 2023 | 1 | 7 | 8 | | 2024 | 5 | 3 | 8 | | 2025 | 8 | 5 | 13 | | 2026 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphocytes, Tumor-Infiltrating" by people in Profiles.
-
Liu Y, Carter JM, Ma Y, Deshmukh SK, Sledge GW, Balko JM, Kachergus JM, Shi J, Gregory M, Gong J, Joensuu H, Perez EA, Stover D, Carey L, Sikov WM, Leon-Ferre R, Knutson KL, Boughey JC, Ingle JN, Kalari KR, Couch FJ, Asmann YW, Goetz MP, Thompson EA, Chumsri S. Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer. J Immunother Cancer. 2026 Jun 03; 14(6).
-
Garza B, Calhoun J, Norman PJ, Cline N, Kichula KM, Farias TDJ, Sams S, Boorgula MP, Danhorn T, Haugen BR, French JD. Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers. J Clin Endocrinol Metab. 2026 Apr 22; 111(5):e1289-e1301.
-
Yamada H, Yamada R, Komohara Y, Pan C, Yoshii D, Yano H, Matsubara E, Shinchi Y, Tsukamoto H, Fujiwara Y, Ikeda K, Suzuki M. Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome. Cancer Immunol Immunother. 2026 Feb 28; 75(3).
-
Tomar MS, Raina K, Mishra N, Kant R, Fox JT, Agarwal C, Agarwal R. Distinct Tumor Infiltrating Immune Cell Profiles in Mice by Non-Steroidal Anti-Inflammatory Drugs (Aspirin and Naproxen) During TMPRSS2-ERG (Fusion)-Driven and Non-Fusion Driven Prostate Cancer. Mol Carcinog. 2026 May; 65(5):589-602.
-
Hoyt-Miggelbrink AM, Waibl Polania J, Wachsmuth L, Lorrey S, Mohan A, Hardigan A, Blandford E, Lerner E, Wilkinson D, Hotchkiss KM, Cook S, Hemmers S, Patel A, Ayasoufi K, Fecci P. Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. Clin Cancer Res. 2026 Feb 17; 32(4):782-800.
-
Lenkala D, Kohler J, McCarthy B, Nelson M, Bakker NAM, de Boer R, Jackson EK, Sheen JHF, Hannes S, Esaulova E, Stewart K, Gottstein C, Attanasio J, Brown FD, Hymson S, Meda S, van Zon M, Scheij S, Voogd R, Raud B, Xu Z, Borgers JSW, Rohaan MW, Balogh KN, Poran A, Rooney M, Dong JZ, Srouji JR, Juneja VR, Arieta CM, Nijenhuis CM, Nuijen B, DeMario M, Manson K, Schumacher TNM, Gaynor RB, Haanen JB, van den Berg JH, van Buuren MM. NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy. Nat Commun. 2026 Feb 05; 17(1).
-
Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Sci Rep. 2025 Oct 23; 15(1):37112.
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
-
Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19; 16(1):7717.
-
Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025 Dec; 14(1):2546402.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|